SmallCaps Podcast

Site Group International (ASX: SIT) international operations director Vernon Wills joins Small Caps to discuss the company’s plan to exceed former milestones post heavy disruption by Covid.

Site is returning to form with circa $31 million revenue projected in FY2025, most notably through developing and upskilling the workforce in Saudi Arabia in partnership with the world’s most profitable company, oil giant Saudi Aramco.

Site provides training services for oil and gas, construction, mining, hospitality and industrial sectors and its blue chip clients also include ExxonMobil, Shell and OceanaGold.

Article:
https://smallcaps.com.au/site-international-launches-raising-progress-philippines-development/

For more information on Site Group International: https://smallcaps.com.au/stocks/SIT/

See omnystudio.com/listener for privacy information.

David Hunter, chief macro strategist at Contrarian Macro Advisors, joins Small Caps to share his views on where the stock market is headed, gold, silver, the US dollar and more...

David is an investment professional with 25 years of investment management experience and 20 years as a sell-side strategist with strong expertise in macroeconomic analysis and portfolio management.

His macro capabilities combined with a contrarian philosophy have allowed him to forecast economic cycles and spot market trends well ahead of the consensus. 

See omnystudio.com/listener for privacy information.

RemSense Technologies (ASX: REM) managing director and CEO Steve Brown joins Small Caps to discuss the company’s accelerated growth plans for its core product virtualplant, which is a photographic asset visualisation platform that delivers greater productivity and increased safety at a reduced cost.

The platform combines artificial intelligence and virtual reality to create a visual digital twin that can integrate with a client’s operations and asset management systems.

Mr Brown says virtualplant supports ongoing monitoring, operational control, induction and training, auditing, planning, capital upgrades, maintenance and shutdowns for staff, contractors and suppliers.

Article:
https://smallcaps.com.au/remsense-builds-cash-reserves-fast-track-growth/

For more information on RemSense Technologies: https://smallcaps.com.au/stocks/REM/

See omnystudio.com/listener for privacy information.

Legacy Minerals (ASX: LGM) managing director Christopher Byrne joins Small Caps to discuss Newmont’s recent agreement to farm into its Bauloora gold project in New South Wales.

Under the deal, Newmont can earn up to 80% of the project by spending $15 million on exploration over two stages.

Mr Byrne said securing the world’s largest gold mining company as a long-term partner for Bauloora was of huge significance.

Article:
https://smallcaps.com.au/legacy-minerals-farm-in-joint-venture-newmont-exploration-bauloora-gold-project/

For more information on Legacy Minerals:
https://smallcaps.com.au/stocks/LGM/

See omnystudio.com/listener for privacy information.

Nova Minerals (ASX: NVA) chief executive officer Christopher Gerteisen joins Small Caps to discuss the most recent expansion to resources at its flagship Estelle gold project in Alaska.

The massive resource now contains 9.9Moz of gold and has even more upside potential at the RPM target, which is already one of the world’s largest high-grade undeveloped open pit gold deposits.

While it continues to build its resource inventory, Nova is undertaking scoping and pre-feasibility work to underpin project development and financing.

Article:
https://smallcaps.com.au/nova-minerals-unveils-1-1bt-global-resource-estelle-gold-project-alaska/

For more information on Nova Minerals:
https://smallcaps.com.au/stocks/NVA/

See omnystudio.com/listener for privacy information.

Astral Resources (ASX: AAR) managing director Marc Ducler joins Small Caps to discuss the company’s aggressive exploration program across its key gold projects in Western Australia’s eastern goldfields, which continues to return high-grade gold hits.

Global resources now total 1.15Moz of contained gold, with the Mandilla project contributing 1.03Moz.

As well as Mandilla, Astral is exploring Feysville, which is only 14km south of the world renowned Kalgoorlie Super Pit.

Articles:
https://smallcaps.com.au/astral-confirms-high-grade-gold-zone-outside-mandilla-gold-resource/
https://smallcaps.com.au/astral-resources-aggressively-builds-gold-inventory-tier-one-mining-district/

For more information on Astral Resources:
https://smallcaps.com.au/stocks/AAR/

See omnystudio.com/listener for privacy information.

Altech Batteries (ASX: ATC) managing director Iggy Tan joins Small Caps to discuss the launch of its new battery pack designed for the renewable energy storage market.

Designed in collaboration with German partner Fraunhofer IKTS, the product known as GridPack uses sodium ions (commonly found in table salt) rather than lithium, cobalt, graphite or copper.

Altech says this makes it up to 40% cheaper to produce and lessens exposure to critical metal price rises and supply chain issues. A definitive feasibility study on the product is currently underway.

Articles:
https://smallcaps.com.au/altech-batteries-fraunhofer-launch-design-gridpack-sodium-chloride-battery-pack/
https://smallcaps.com.au/altech-batteries-receives-first-payment-sale-german-subsidiary-company/
https://smallcaps.com.au/altech-chemicals-begins-commissioning-wet-circuit-silumina-anodes-pilot-plant/

For more information on Altech Batteries:
https://smallcaps.com.au/stocks/ATC/

See omnystudio.com/listener for privacy information.

InhaleRx (ASX: IRX) chief executive officer Darryl Davies joins Small Caps to discuss the company’s development plans for its novel inhaled cannabinoid formulation IRX211 in treating complex regional pain syndrome (CRPS).

Mr Davies said the trial will begin recruiting patients in May.

InhaleRx’s strategy is to develop novel cannabinoid-derived drug device combination medicines to treat areas of unmet need in pain management and mental health.

Articles:
https://smallcaps.com.au/inhalerx-ethics-approval-phase-1-trial-novel-drug-irx211-treating-crps/
https://smallcaps.com.au/inhalerx-makes-progress-inhaled-cannabinoid-drugs-crps-panic-disorder/
https://smallcaps.com.au/inhalerx-moves-forward-clinical-trials-drugs-address-mental-health-complex-pain/

For more information on InhaleRx:
https://smallcaps.com.au/stocks/IRX/

See omnystudio.com/listener for privacy information.

Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the latest news in the development of its CAR-T therapy CHM 2101.

Ms Chow says the cell therapy company received positive feedback from a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) in the lead up to a phase 1A study of the drug in treating gastrointestinal and neuroendocrine tumours.

The FDA’s responses provide a clear path to an IND submission for CHM 2101. Chimeric is also evaluating another novel CAR-T therapy, CHM 1101, to treat recurrent or progressive glioblastoma (brain cancer).

Articles:
https://smallcaps.com.au/chimeric-therapeutics-reveals-positive-pre-ind-us-fda-chm-2101/
https://smallcaps.com.au/chimeric-therapeutics-doses-final-cohort-brain-cancer-clinical-trial-advances-chm-2101-candidate/

For more information on Chimeric Therapeutics:
https://smallcaps.com.au/stocks/CHM/

See omnystudio.com/listener for privacy information.

Challenger Exploration (ASX: CEL) managing director and chief executive officer Kris Knauer joins Small Caps to discuss the company’s activities at its Hualilan gold, silver, zinc and lead project in Argentina.

The resource now totals 2.8Moz of gold equivalent and has a higher-grade component of 2.1Moz at 3.1g/t gold equivalent.

Mr Knauer says it's an outstanding result and the resource is enough to support development.

Article:
https://smallcaps.com.au/challenger-exploration-reveals-updated-resource-hualilan-outstanding-drill-results/

For more information on Challenger Exploration: https://smallcaps.com.au/stocks/CEL/

See omnystudio.com/listener for privacy information.